Natera Inc (NTRA) reported quarterly earnings results on Thursday, Aug-4-2016. The company reported $-0.46 EPS for the quarter. Analysts had a consensus estimate of $-0.46. The company posted revenue of $52.00 million in the period, compared to analysts expectations of $51.91 million. The company’s revenue was up 15.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.40 EPS.
Many Wall Street Analysts have commented on Natera Inc. Company shares were Reiterated by The Benchmark Company on May 23, 2016 to “Buy”, Firm has raised the Price Target to $ 16 from a previous price target of $15 .Company shares were Reiterated by The Benchmark Company on May 11, 2016 to “Buy”, Firm has raised the Price Target to $ 15 from a previous price target of $14 .
Natera Inc opened for trading at $12.98 and hit $13.36 on the upside on Tusday, eventually ending the session at $13.05, with a gain of 0.08% or 0.01 points. The heightened volatility saw the trading volume jump to 1,23,542 shares. Company has a market cap of $669 M.
In a different news, on Jul 8, 2016, Herm Rosenman (Chief Financial Officer) sold 1,824 shares at $12.10 per share price. According to the SEC, on Jul 5, 2016, Matthew Rabinowitz (Chief Executive Officer) sold 104,892 shares at $12.12 per share price. On Jun 21, 2016, Jonathan Sheena (Chief Technology Officer) sold 188,442 shares at $11.94 per share price, according to the Form-4 filing with the securities and exchange commission.
Natera Inc. is a diagnostics company. The Company has molecular and bioinformatics technology that it deploys to change genetic diseases across the world. Its molecular assays measure various regions across the genome from samples as small as a single cell. Its statistical algorithms combine these measurements with the available data to detect a range of serious conditions. It is engaged in developing products for various oncology applications. In addition to its direct sales force in the United States the Company has a global network of over 70 laboratory and distribution partners. It has introduced a cloud-based distribution model. It also has launched seven molecular diagnostic tests. The Company launched Panorama which is its non-invasive prenatal test (NIPT). Its products include Pre-implantation Genetic Screening Pre-implantation Genetic Diagnosis Products of Conception Non-Invasive Paternity Testing High Throughput Carrier Screening and Non-Invasive Prenatal Testing.